Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma
Authors:
- Jean-Baptiste BachetJBJean-Baptiste Bachet
- Fabien GayFGFabien Gay
- Raphaël MaréchalRMRaphaël Maréchal
- Marie-Pierre GalaisMGMarie-Pierre Galais
- Antoine AdenisAAAntoine Adenis
- David SalakoDSDavid Salako
- David Salako MscDMDavid Salako Msc
- Jerome CrosJerome Cros
- Pieter DemetterPDPieter Demetter
- Magali SvrcekMSMagali Svrcek
- Armelle Bardier-DupasABArmelle Bardier-Dupas
- Jean-François EmileJEJean-François Emile
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 44 (7) , 1141-1147
Abstract
Asparaginase encapsulated in erythrocytes (ERY-ASP) is a potentially effective drug in patients with pancreatic adenocarcinoma (PAC) with null/low asparagine synthetase (ASNS) expression. Our aims were to assess ASNS expression in PAC from a large cohort and its prognostic and/or predictive value and to conduct a phase I trial with ERY-ASP in patients with metastatic PAC. Asparagine synthetase expression was evaluated using immunohistochemistry in resected PAC (471 patients) and in pairs of primary tumor and metastases (55 patients). Twelve patients were included in the phase I trial and received a single administration of ERY-ASP (25-150 IU/kg). Null/low ASNS expression was found in 79.4% of the resected PAC with a high concordance between primary tumor and metastases. Asparagine synthetase expression was significantly correlated with sex and CXCR4 expression. In the phase I trial, ERY-ASP was well tolerated by patients with metastatic PAC. No patient had DLTs, and 6 patients had at least 1 ERY-ASP causally related adverse event out of the 12 adverse events reported. Given the high rate of PAC with null/low ASNS expression and the good tolerability profile of ERY-ASP, ERY-ASP should be evaluated in further clinical studies in metastatic PAC.Keywords
This publication has 33 references indexed in Scilit:
- How I treat older patients with ALLBlood, 2013
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelLeukemia & Lymphoma, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trialBritish Journal of Haematology, 2011
- Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotypeBritish Journal of Cancer, 2010
- Finding value in the U.S. Food and Drug Administration's fast track programDrug News & Perspectives, 2009
- Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell linesPediatric Blood & Cancer, 2007
- Enhanced Expression of Asparagine Synthetase under Glucose-Deprived Conditions Protects Pancreatic Cancer Cells from Apoptosis Induced by Glucose Deprivation and CisplatinCancer Research, 2007
- Expression profiling of PC-3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostateEuropean Journal of Clinical Investigation, 2007
- Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemiaBlood, 2006